Tenax Selling And Marketing Expenses vs Cost Of Revenue Analysis

TENX Stock  USD 6.37  0.04  0.62%   
Tenax Therapeutics financial indicator trend analysis is much more than just breaking down Tenax Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tenax Therapeutics is a good investment. Please check the relationship between Tenax Therapeutics Selling And Marketing Expenses and its Cost Of Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.

Selling And Marketing Expenses vs Cost Of Revenue

Selling And Marketing Expenses vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tenax Therapeutics Selling And Marketing Expenses account and Cost Of Revenue. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Tenax Therapeutics' Selling And Marketing Expenses and Cost Of Revenue is 0.53. Overlapping area represents the amount of variation of Selling And Marketing Expenses that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Tenax Therapeutics, assuming nothing else is changed. The correlation between historical values of Tenax Therapeutics' Selling And Marketing Expenses and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Selling And Marketing Expenses of Tenax Therapeutics are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Selling And Marketing Expenses i.e., Tenax Therapeutics' Selling And Marketing Expenses and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

0.53
Relationship DirectionPositive 
Relationship StrengthWeak

Selling And Marketing Expenses

Cost Of Revenue

Cost of Revenue is found on Tenax Therapeutics income statement and represents the costs associated with goods and services Tenax Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.
Most indicators from Tenax Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tenax Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenax Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Tenax Stock please use our How to Invest in Tenax Therapeutics guide.At this time, Tenax Therapeutics' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to rise to 0.44 in 2025, whereas Selling General Administrative is likely to drop slightly above 4.9 M in 2025.
 2022 2023 2024 2025 (projected)
Other Operating Expenses11.1M8.2M9.5M8.4M
Depreciation And Amortization113.3K7.6K8.7K8.3K

Tenax Therapeutics fundamental ratios Correlations

-0.220.190.091.0-0.14-0.990.28-0.160.990.761.00.280.91-0.150.050.891.00.15-0.18-0.18-0.17-0.53-0.40.03-0.3
-0.22-0.04-0.05-0.250.70.270.33-0.04-0.23-0.13-0.25-0.20.17-0.15-0.40.16-0.24-0.2-0.1-0.10.720.090.33-0.160.56
0.19-0.040.760.16-0.19-0.140.04-0.130.140.330.16-0.080.11-0.16-0.010.380.16-0.19-0.18-0.18-0.17-0.06-0.340.05-0.06
0.09-0.050.760.06-0.37-0.06-0.240.490.070.10.070.39-0.060.460.380.290.080.21-0.34-0.33-0.30.05-0.18-0.19-0.02
1.0-0.250.160.06-0.16-1.00.26-0.160.990.761.00.280.9-0.150.070.871.00.16-0.17-0.17-0.2-0.53-0.410.04-0.32
-0.140.7-0.19-0.37-0.160.170.48-0.4-0.15-0.04-0.18-0.330.21-0.52-0.610.11-0.18-0.380.160.150.980.010.430.110.6
-0.990.27-0.14-0.06-1.00.17-0.230.14-1.0-0.75-1.0-0.3-0.880.13-0.1-0.85-1.0-0.180.180.180.210.530.4-0.020.33
0.280.330.04-0.240.260.48-0.23-0.520.240.290.24-0.230.49-0.59-0.90.380.23-0.380.610.610.39-0.190.210.680.45
-0.16-0.04-0.130.49-0.16-0.40.14-0.52-0.12-0.38-0.140.77-0.30.880.65-0.12-0.120.43-0.29-0.28-0.320.220.08-0.4-0.2
0.99-0.230.140.070.99-0.15-1.00.24-0.120.751.00.30.9-0.120.090.871.00.18-0.19-0.19-0.18-0.53-0.380.01-0.31
0.76-0.130.330.10.76-0.04-0.750.29-0.380.750.75-0.210.72-0.29-0.060.720.750.04-0.11-0.11-0.1-0.66-0.380.18-0.18
1.0-0.250.160.071.0-0.18-1.00.24-0.141.00.750.290.9-0.130.090.871.00.16-0.2-0.2-0.21-0.53-0.420.01-0.33
0.28-0.2-0.080.390.28-0.33-0.3-0.230.770.3-0.210.290.120.640.450.260.310.4-0.2-0.19-0.270.07-0.06-0.25-0.29
0.910.170.11-0.060.90.21-0.880.49-0.30.90.720.90.12-0.34-0.210.930.89-0.03-0.16-0.160.17-0.5-0.280.02-0.04
-0.15-0.15-0.160.46-0.15-0.520.13-0.590.88-0.12-0.29-0.130.64-0.340.72-0.18-0.110.75-0.22-0.22-0.440.160.18-0.31-0.25
0.05-0.4-0.010.380.07-0.61-0.1-0.90.650.09-0.060.090.45-0.210.72-0.090.10.57-0.63-0.63-0.520.02-0.28-0.65-0.56
0.890.160.380.290.870.11-0.850.38-0.120.870.720.870.260.93-0.18-0.090.870.05-0.26-0.260.09-0.46-0.29-0.04-0.02
1.0-0.240.160.081.0-0.18-1.00.23-0.121.00.751.00.310.89-0.110.10.870.17-0.21-0.21-0.21-0.53-0.410.0-0.33
0.15-0.2-0.190.210.16-0.38-0.18-0.380.430.180.040.160.4-0.030.750.570.050.17-0.03-0.03-0.37-0.090.31-0.05-0.36
-0.18-0.1-0.18-0.34-0.170.160.180.61-0.29-0.19-0.11-0.2-0.2-0.16-0.22-0.63-0.26-0.21-0.031.00.050.060.590.950.06
-0.18-0.1-0.18-0.33-0.170.150.180.61-0.28-0.19-0.11-0.2-0.19-0.16-0.22-0.63-0.26-0.21-0.031.00.040.060.590.950.06
-0.170.72-0.17-0.3-0.20.980.210.39-0.32-0.18-0.1-0.21-0.270.17-0.44-0.520.09-0.21-0.370.050.040.130.4-0.010.61
-0.530.09-0.060.05-0.530.010.53-0.190.22-0.53-0.66-0.530.07-0.50.160.02-0.46-0.53-0.090.060.060.130.22-0.110.13
-0.40.33-0.34-0.18-0.410.430.40.210.08-0.38-0.38-0.42-0.06-0.280.18-0.28-0.29-0.410.310.590.590.40.220.440.28
0.03-0.160.05-0.190.040.11-0.020.68-0.40.010.180.01-0.250.02-0.31-0.65-0.040.0-0.050.950.95-0.01-0.110.440.01
-0.30.56-0.06-0.02-0.320.60.330.45-0.2-0.31-0.18-0.33-0.29-0.04-0.25-0.56-0.02-0.33-0.360.060.060.610.130.280.01
Click cells to compare fundamentals

Tenax Therapeutics Account Relationship Matchups

Tenax Therapeutics fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets6.9M6.0M3.4M11.7M13.4M15.5M
Short Long Term Debt Total305.0K290.8K807.9K500.9K576.0K589.8K
Other Current Liab1.2M597.1K655.7K1.0M1.2M790.7K
Total Current Liabilities2.1M1.6M1.8M3.6M4.1M4.3M
Total Stockholder Equity4.6M4.2M1.5M8.1M9.3M12.7M
Property Plant And Equipment Net8.5K176.0K64.8K294.8K186.7K0.0
Net Debt(5.9M)(5.3M)(1.3M)(9.3M)(8.4M)(8.8M)
Retained Earnings(246.0M)(278.5M)(289.5M)(297.3M)(267.5M)(254.2M)
Accounts Payable757.9K859.6K448.4K2.1M2.4M2.5M
Cash6.3M5.6M2.1M9.8M11.3M9.6M
Non Current Assets Total73.2K303.2K196.2K1.1K1.3K1.2K
Cash And Short Term Investments6.7M5.6M2.1M9.8M11.3M10.0M
Common Stock Shares Outstanding6.5K12.9K18.4K248.4K285.7K300K
Liabilities And Stockholders Equity6.9M6.0M3.4M11.7M13.4M15.5M
Non Current Liabilities Total749.8K60.4K124.2K183.6K64.2K0.0
Other Current Assets82.6K105.1K1.1M1.9M2.2M2.3M
Other Stockholder Equity250.6M282.7M291.0M305.4M351.2M368.7M
Total Liab2.2M1.7M1.9M3.6M4.1M2.8M
Total Current Assets6.8M5.7M3.2M11.7M13.4M10.5M
Short Term Debt180.9K107.2K743.7K500.9K576.0K604.8K
Common Stock1.3K2.5K4.6K30.027.025.65
Property Plant And Equipment Gross8.5K176.0K6.0K294.8K186.7K0.0
Property Plant Equipment8.5K6.6K64.8K294.8K265.3K172.3K
Net Tangible Assets11.8M3.8M4.6M4.2M3.8M3.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Tenax Stock Analysis

When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.